Memorial Sloan Kettering has advanced the diagnosis and treatment of melanoma around the globe, transforming the outlook for countless people diagnosed with this cancer. Our physicians and scientists have been at the forefront in identifying melanoma risk factors, creating noninvasive diagnostic techniques, and developing new treatments that prolong survival even in patients with advanced melanoma.  Through our clinical trials program, patients can have access to experimental therapies that are not readily available elsewhere.

Making an Appointment

Call 800-525-2225
Mon–Fri, 8:30 AM–5:30 PM, ET

Watch a video|For referring physicians

More Science. Less Fear.
It’s Time to Change How the World Treats Cancer.

Learn how we’re making what was impossible yesterday possible today.

Pictured: Jedd Wolchok
Clinical Trials

Choosing Memorial Sloan Kettering may give you access to new melanoma therapies before they are widely available elsewhere.

Pictured: James
James’s Story

James had advanced melanoma and dwindling treatment options when his doctors enrolled him in a clinical trial of ipilimumab, an innovative immunotherapy developed at Memorial Sloan Kettering.

Prediction Tools

Use our online nomogram to calculate the risk that cancer has spread to the lymph nodes in patients with melanoma. Results can help in making important treatment decisions.

Pictured: Kishwer Nehal
Approaches to Managing Melanoma

Melanoma experts from Memorial Sloan Kettering explain why this disease requires different treatment approaches than other skin cancers.

Pictured: Charlotte Ariyan
New Treatment Options for Advanced Melanoma

New therapies have improved survival for many patients with metastatic melanoma, according to Skin Memorial Sloan Kettering experts.

Pictured: Paul Chapman
New Directions in Melanoma Research

Medical oncologist Paul Chapman of Memorial Sloan Kettering describes cutting-edge research to improve the treatment of metastatic melanoma.

Pictured: Kishwer Nehal
Managing Melanoma
Pictured: Charlotte Ariyan
New Treatment Options
Pictured: Paul Chapman
Melanoma Research